Evaluation of Drug–Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25)

期刊论文
出版模式：

开放获取
发表日期：

2026年6月13日

查看全文

Giandomenico Roviello,
Mattia Alberto Di Civita,
Daniele Santini,
Elisabetta Gambale,
Lidia Strigari,
Simone Scagnoli,
Laura Pappalardo,
Andrea Torchia,
Andrea Botticelli,
Serena Pillozzi,
Lorenzo Antonuzzo

摘要

Introduction

Polypharmacy is common in patients with advanced urothelial carcinoma (UC) receiving avelumab maintenance therapy, raising concerns about potential drug–drug interactions (DDIs).

Methods

We retrospectively analyzed patients enrolled in the multicenter MALVA study treated with avelumab maintenance. Concomitant medications were assessed using the Drug Interaction and Pharmacogenomics Information Network (Drug-PIN®). Drug-PIN® scores were calculated with and without avelumab and correlated with overall survival (OS) and progression-free survival (PFS).

Results

Among 115 patients, Drug-PIN® scores showed wide inter-patient variability but were not significantly influenced by inclusion of avelumab. No significant differences in OS or PFS were observed across Drug-PIN® risk categories.

Conclusion

In this real-world cohort, polypharmacy and Drug-PIN® score did not impact survival outcomes, suggesting that, within the limitations of this exploratory analysis, Drug-PIN®-assessed DDI burden was not associated with survival outcomes in patients receiving avelumab maintenance therapy.